Targeting the Ghrelin Receptor: Oral Drug Development Including Cortistatin Cross-Reactivity

Orally active GH secretagogues and the endogenous peptide cortistatin both target the ghrelin receptor, with cortistatin's cross-reactivity revealing additional therapeutic dimensions beyond GH release and appetite.

Deghenghi, Romano et al.·Endocrine·2003·Moderate EvidenceReview
RPEP-00809ReviewModerate Evidence2003RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
Review
Evidence
Moderate Evidence
Sample
Not reported

What This Study Found

Orally active GH secretagogues and cortistatin (a somatostatin-related peptide) both target the ghrelin receptor, expanding the receptor's known ligand repertoire and therapeutic targeting possibilities.

Key Numbers

How They Did This

Review of oral GH secretagogue development (peptide and non-peptide) and the emerging pharmacology of cortistatin-GHS-R interaction.

Why This Research Matters

The ghrelin receptor integrates signals from multiple peptide families. Understanding this broader ligand landscape improves drug design and predicts clinical effects more accurately.

The Bigger Picture

Receptors rarely respond to just one ligand in nature. The ghrelin receptor's response to both ghrelin and cortistatin reveals a richer signaling system than assumed.

What This Study Doesn't Tell Us

Review from 2003. The clinical significance of cortistatin-GHS-R interaction was still being explored.

Questions This Raises

  • ?Does cortistatin modulate ghrelin's appetite effects?
  • ?Could cortistatin analogs be developed for specific GHS-R therapeutic targeting?
  • ?Do cortistatin levels affect GH secretagogue drug efficacy?

Trust & Context

Key Stat:
Multi-ligand receptor The ghrelin receptor responds to ghrelin, synthetic GHS, AND cortistatin — a richer pharmacology than one ligand would suggest
Evidence Grade:
Moderate evidence from a review integrating drug development data with novel receptor pharmacology.
Study Age:
Published in 2003. The cortistatin-ghrelin receptor interaction has been further characterized.
Original Title:
Targeting the ghrelin receptor: orally active GHS and cortistatin analogs.
Published In:
Endocrine, 22(1), 13-8 (2003)
Database ID:
RPEP-00809

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / ObservationalSnapshot without intervening
This study
Case Report / Animal Study

Summarizes existing research on a topic.

What do these levels mean? →

Frequently Asked Questions

What is cortistatin?

A brain peptide related to somatostatin that unexpectedly also activates the ghrelin receptor. This means the ghrelin system integrates signals from multiple peptide sources.

Why does this matter for drug development?

If the ghrelin receptor responds to multiple natural peptides, drugs targeting it will have broader effects than expected. Understanding the full ligand landscape enables more precise drug design.

Read More on RethinkPeptides

Cite This Study

RPEP-00809·https://rethinkpeptides.com/research/RPEP-00809

APA

Deghenghi, Romano; Broglio, Fabio; Papotti, Mauro; Muccioli, Giampiero; Ghigo, Ezio. (2003). Targeting the ghrelin receptor: orally active GHS and cortistatin analogs.. Endocrine, 22(1), 13-8.

MLA

Deghenghi, Romano, et al. "Targeting the ghrelin receptor: orally active GHS and cortistatin analogs.." Endocrine, 2003.

RethinkPeptides

RethinkPeptides Research Database. "Targeting the ghrelin receptor: orally active GHS and cortis..." RPEP-00809. Retrieved from https://rethinkpeptides.com/research/deghenghi-2003-targeting-the-ghrelin-receptor

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.